Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing Clinical Development

Author: Benzinga Newsdesk | June 26, 2024 09:08am

Posted In: NRBO